Share Price and Basic Stock Data
Last Updated: January 3, 2026, 11:48 am
| PEG Ratio | -6.60 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
MK Proteins Ltd operates in the Edible Oils and Solvent Extraction industry, with a current market capitalization of ₹224 Cr. The company reported sales of ₹315 Cr for the fiscal year ending March 2023, reflecting a growth from ₹245 Cr in March 2024 and ₹268 Cr in March 2025, indicating a fluctuating revenue trend over the years. The quarterly sales figures show an increase from ₹53.59 Cr in March 2017 to ₹76.20 Cr in June 2023, followed by significant growth to ₹86.87 Cr in March 2024. However, sales dipped to ₹57.33 Cr in June 2024 and further to ₹33.69 Cr in September 2024 before rebounding to ₹137.20 Cr by March 2025. This volatility suggests that while there are growth opportunities, the company faces challenges in maintaining consistent sales momentum.
Profitability and Efficiency Metrics
MK Proteins Ltd reported a net profit of ₹11 Cr for the fiscal year ending March 2025, a decrease from ₹11 Cr in March 2024, indicating profitability challenges. The operating profit margin (OPM) stood at 4.79%, showcasing a slight decline from previous years, with a peak of 9.70% in March 2024. The interest coverage ratio (ICR) was robust at 11.68x, reflecting the company’s ability to meet interest obligations comfortably. However, the cash conversion cycle (CCC) has lengthened to 142 days, indicating potential inefficiencies in inventory management and receivables collection. The return on equity (ROE) was reported at 12.4%, while the return on capital employed (ROCE) stood at 12.9%, both of which are relatively low compared to industry benchmarks. This suggests that while MK Proteins is generating profits, the capital efficiency could be improved.
Balance Sheet Strength and Financial Ratios
The balance sheet of MK Proteins Ltd shows total assets of ₹131 Cr and total liabilities of ₹131 Cr as of March 2025, indicating a balanced financial structure. The company reported reserves of ₹36 Cr and minimal borrowings of ₹2 Cr, which is significantly low, reflecting a conservative approach to leverage. The debt-to-equity ratio stood at 0.54x, which is relatively low, suggesting that the company is not heavily reliant on debt for financing. However, the price-to-book value ratio of 3.26x indicates that the stock may be overvalued relative to its book value. Additionally, the current ratio is at 2.01x, demonstrating adequate short-term liquidity. The inventory turnover ratio of 2.81x suggests that the company is managing its inventory effectively, although a higher turnover rate would be preferable in the sector.
Shareholding Pattern and Investor Confidence
MK Proteins Ltd has a stable shareholding pattern, with promoters holding 74.82% of the company as of March 2025. This significant promoter stake reflects strong confidence from the management in the company’s future prospects. The public shareholding is at 25.17%, which indicates a growing interest among retail investors, as evidenced by the increase in the number of shareholders from 344 in June 2023 to 72,294 in March 2025. However, foreign institutional investors (FIIs) have not invested in the company, which may indicate a lack of confidence from larger institutional players. The increase in public shareholders signals potential for increased liquidity in the market, but the absence of FIIs could be a potential risk factor for the stock’s performance. Maintaining this balance of ownership is crucial for sustaining investor confidence.
Outlook, Risks, and Final Insight
Looking ahead, MK Proteins Ltd faces both opportunities and challenges. The company’s ability to sustain revenue growth will depend on effectively managing operational efficiencies and optimizing its supply chain to reduce the cash conversion cycle. Risks include market volatility in the edible oils sector and potential fluctuations in raw material prices, which could impact profitability. Moreover, the company’s reliance on a high promoter stake without institutional backing may deter some investors. On the flip side, the company’s strong ICR and low debt levels present a solid foundation for growth. If MK Proteins can leverage its existing strengths to enhance profitability and attract institutional investors, it could see a more favorable outlook in the coming fiscal years. However, without addressing operational inefficiencies, the company may struggle to capitalize on its growth potential.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modi Naturals Ltd | 475 Cr. | 357 | 610/320 | 13.0 | 107 | 0.00 % | 18.7 % | 29.2 % | 10.0 |
| IEL Ltd | 93.0 Cr. | 7.13 | 10.3/3.87 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 312 Cr. | 1.66 | 3.62/1.52 | 218 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 69.9 Cr. | 2.93 | 3.95/1.45 | 27.2 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 3,812 Cr. | 1,362 | 3,633/321 | 1,878 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| Industry Average | 10,569.57 Cr | 174.33 | 147.55 | 37.26 | 0.17% | 14.31% | 12.90% | 4.29 |
Quarterly Result
| Metric | Mar 2017 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 53.59 | 76.20 | 13.64 | 68.86 | 86.87 | 57.33 | 33.69 | 39.48 | 137.20 | 114.95 |
| Expenses | 51.69 | 72.21 | 13.00 | 65.30 | 78.44 | 53.59 | 31.46 | 37.69 | 132.55 | 109.44 |
| Operating Profit | 1.90 | 3.99 | 0.64 | 3.56 | 8.43 | 3.74 | 2.23 | 1.79 | 4.65 | 5.51 |
| OPM % | 3.55% | 5.24% | 4.69% | 5.17% | 9.70% | 6.52% | 6.62% | 4.53% | 3.39% | 4.79% |
| Other Income | 0.01 | 0.00 | 0.03 | 0.01 | 0.41 | 0.00 | 0.21 | 0.25 | 0.02 | 0.00 |
| Interest | 0.69 | 0.52 | 0.04 | 0.11 | 0.40 | 0.33 | 0.03 | 0.07 | 0.67 | 0.70 |
| Depreciation | 0.30 | 0.12 | 0.12 | 0.12 | 0.18 | 0.07 | 0.07 | 0.11 | 0.09 | 0.10 |
| Profit before tax | 0.92 | 3.35 | 0.51 | 3.34 | 8.26 | 3.34 | 2.34 | 1.86 | 3.91 | 4.71 |
| Tax % | 36.96% | 25.67% | 21.57% | 25.75% | 29.42% | 25.45% | 25.21% | 25.81% | 28.64% | 25.27% |
| Net Profit | 0.57 | 2.49 | 0.41 | 2.48 | 5.83 | 2.48 | 1.74 | 1.38 | 2.80 | 3.51 |
| EPS in Rs | 0.02 | 0.07 | 0.01 | 0.07 | 0.16 | 0.07 | 0.05 | 0.04 | 0.07 | 0.09 |
Last Updated: August 20, 2025, 7:35 am
Below is a detailed analysis of the quarterly data for MK Proteins Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 114.95 Cr.. The value appears to be declining and may need further review. It has decreased from 137.20 Cr. (Mar 2025) to 114.95 Cr., marking a decrease of 22.25 Cr..
- For Expenses, as of Jun 2025, the value is 109.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 132.55 Cr. (Mar 2025) to 109.44 Cr., marking a decrease of 23.11 Cr..
- For Operating Profit, as of Jun 2025, the value is 5.51 Cr.. The value appears strong and on an upward trend. It has increased from 4.65 Cr. (Mar 2025) to 5.51 Cr., marking an increase of 0.86 Cr..
- For OPM %, as of Jun 2025, the value is 4.79%. The value appears strong and on an upward trend. It has increased from 3.39% (Mar 2025) to 4.79%, marking an increase of 1.40%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.02 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Jun 2025, the value is 0.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.67 Cr. (Mar 2025) to 0.70 Cr., marking an increase of 0.03 Cr..
- For Depreciation, as of Jun 2025, the value is 0.10 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.09 Cr. (Mar 2025) to 0.10 Cr., marking an increase of 0.01 Cr..
- For Profit before tax, as of Jun 2025, the value is 4.71 Cr.. The value appears strong and on an upward trend. It has increased from 3.91 Cr. (Mar 2025) to 4.71 Cr., marking an increase of 0.80 Cr..
- For Tax %, as of Jun 2025, the value is 25.27%. The value appears to be improving (decreasing) as expected. It has decreased from 28.64% (Mar 2025) to 25.27%, marking a decrease of 3.37%.
- For Net Profit, as of Jun 2025, the value is 3.51 Cr.. The value appears strong and on an upward trend. It has increased from 2.80 Cr. (Mar 2025) to 3.51 Cr., marking an increase of 0.71 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.09. The value appears strong and on an upward trend. It has increased from 0.07 (Mar 2025) to 0.09, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:02 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 122 | 123 | 145 | 165 | 172 | 157 | 194 | 311 | 256 | 315 | 245 | 268 | 324 |
| Expenses | 119 | 119 | 141 | 160 | 166 | 152 | 189 | 295 | 240 | 298 | 229 | 255 | 311 |
| Operating Profit | 3 | 4 | 4 | 5 | 6 | 5 | 5 | 16 | 16 | 17 | 17 | 13 | 13 |
| OPM % | 2% | 3% | 3% | 3% | 3% | 3% | 2% | 5% | 6% | 5% | 7% | 5% | 4% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 2 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
| Profit before tax | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 14 | 14 | 15 | 15 | 11 | 11 |
| Tax % | 33% | 32% | 31% | 35% | 35% | 28% | 26% | 27% | 27% | 27% | 28% | 27% | |
| Net Profit | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 10 | 10 | 11 | 11 | 8 | 8 |
| EPS in Rs | 0.82 | 1.40 | 1.20 | 0.04 | 0.04 | 0.04 | 0.05 | 0.28 | 0.27 | 0.29 | 0.30 | 0.22 | 0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 400.00% | 0.00% | 10.00% | 0.00% | -27.27% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% | 100.00% | -100.00% | 400.00% | -400.00% | 10.00% | -10.00% | -27.27% |
MK Proteins Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 7% |
| 3 Years: | 2% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 35% |
| 3 Years: | -7% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 49% |
| 3 Years: | 39% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 23% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 10:00 am
Balance Sheet
Last Updated: December 10, 2025, 3:01 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.68 | 0.68 | 0.68 | 3 | 4 | 4 | 4 | 4 | 4 | 13 | 38 | 38 | 38 |
| Reserves | 1 | 2 | 3 | 2 | 11 | 13 | 15 | 25 | 35 | 37 | 24 | 32 | 36 |
| Borrowings | 28 | 20 | 26 | 31 | 33 | 26 | 31 | 25 | 37 | 46 | 20 | 39 | 2 |
| Other Liabilities | 2 | 13 | 10 | 12 | 8 | 4 | 7 | 13 | 10 | 8 | 15 | 22 | 4 |
| Total Liabilities | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 | 80 |
| Fixed Assets | 3 | 6 | 7 | 7 | 6 | 4 | 3 | 2 | 3 | 3 | 3 | 4 | 3 |
| CWIP | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 7 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| Other Assets | 26 | 29 | 32 | 40 | 50 | 43 | 53 | 65 | 83 | 100 | 88 | 120 | 66 |
| Total Assets | 32 | 35 | 39 | 47 | 56 | 47 | 57 | 67 | 86 | 103 | 96 | 131 | 80 |
Below is a detailed analysis of the balance sheet data for MK Proteins Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 38.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 38.00 Cr..
- For Reserves, as of Sep 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Mar 2025) to 36.00 Cr., marking an increase of 4.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 39.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 37.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing). It has decreased from 22.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 18.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 80.00 Cr.. The value appears to be improving (decreasing). It has decreased from 131.00 Cr. (Mar 2025) to 80.00 Cr., marking a decrease of 51.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2025) to 3.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 7.00 Cr..
- For Investments, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 4.00 Cr..
- For Other Assets, as of Sep 2025, the value is 66.00 Cr.. The value appears to be declining and may need further review. It has decreased from 120.00 Cr. (Mar 2025) to 66.00 Cr., marking a decrease of 54.00 Cr..
- For Total Assets, as of Sep 2025, the value is 80.00 Cr.. The value appears to be declining and may need further review. It has decreased from 131.00 Cr. (Mar 2025) to 80.00 Cr., marking a decrease of 51.00 Cr..
Notably, the Reserves (36.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -25.00 | -16.00 | -22.00 | -26.00 | -27.00 | -21.00 | -26.00 | -9.00 | -21.00 | -29.00 | -3.00 | -26.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 19 | 16 | 27 | 10 | 39 | 25 | 18 | 24 | 42 | 19 | 5 | 2 |
| Inventory Days | 62 | 70 | 57 | 83 | 69 | 75 | 79 | 48 | 80 | 91 | 134 | 170 |
| Days Payable | 6 | 39 | 22 | 23 | 12 | 6 | 8 | 10 | 8 | 6 | 19 | 29 |
| Cash Conversion Cycle | 75 | 47 | 62 | 70 | 97 | 94 | 89 | 62 | 114 | 104 | 120 | 142 |
| Working Capital Days | 69 | 11 | 9 | 20 | 44 | 32 | 36 | 36 | 55 | 57 | 77 | 81 |
| ROCE % | 10% | 14% | 13% | 12% | 11% | 8% | 8% | 29% | 23% | 20% | 19% | 13% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Diluted EPS (Rs.) | 0.22 | 0.30 | 8.51 | 24.42 | 24.91 |
| Cash EPS (Rs.) | 0.23 | 0.31 | 9.11 | 26.61 | 27.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1.85 | 1.63 | 40.18 | 94.95 | 70.34 |
| Revenue From Operations / Share (Rs.) | 7.13 | 6.54 | 251.64 | 613.52 | 745.89 |
| PBDIT / Share (Rs.) | 0.34 | 0.45 | 13.66 | 37.85 | 38.31 |
| PBIT / Share (Rs.) | 0.33 | 0.44 | 13.06 | 35.66 | 36.13 |
| PBT / Share (Rs.) | 0.30 | 0.41 | 11.67 | 33.67 | 34.34 |
| Net Profit / Share (Rs.) | 0.22 | 0.29 | 8.51 | 24.42 | 24.91 |
| PBDIT Margin (%) | 4.82 | 6.94 | 5.42 | 6.16 | 5.13 |
| PBIT Margin (%) | 4.69 | 6.73 | 5.18 | 5.81 | 4.84 |
| PBT Margin (%) | 4.27 | 6.29 | 4.63 | 5.48 | 4.60 |
| Net Profit Margin (%) | 3.13 | 4.56 | 3.38 | 3.98 | 3.33 |
| Return on Networth / Equity (%) | 12.08 | 18.35 | 21.17 | 25.71 | 35.41 |
| Return on Capital Employeed (%) | 17.54 | 26.54 | 30.87 | 35.13 | 44.53 |
| Return On Assets (%) | 6.43 | 11.64 | 10.14 | 11.82 | 15.42 |
| Long Term Debt / Equity (X) | 0.01 | 0.00 | 0.05 | 0.06 | 0.15 |
| Total Debt / Equity (X) | 0.54 | 0.31 | 0.88 | 0.92 | 0.83 |
| Asset Turnover Ratio (%) | 2.36 | 2.44 | 3.30 | 3.33 | 5.02 |
| Current Ratio (X) | 2.01 | 2.53 | 1.96 | 1.88 | 1.92 |
| Quick Ratio (X) | 0.12 | 0.19 | 0.58 | 0.74 | 0.79 |
| Inventory Turnover Ratio (X) | 2.81 | 2.73 | 4.23 | 4.49 | 5.77 |
| Interest Coverage Ratio (X) | 11.68 | 16.02 | 9.86 | 18.96 | 21.31 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 11.53 | 7.14 | 13.23 | 14.86 |
| Enterprise Value (Cr.) | 264.44 | 389.87 | 957.87 | 116.65 | 57.72 |
| EV / Net Operating Revenue (X) | 0.98 | 1.59 | 3.04 | 0.45 | 0.18 |
| EV / EBITDA (X) | 20.49 | 22.85 | 56.03 | 7.39 | 3.61 |
| MarketCap / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| Price / BV (X) | 3.26 | 6.07 | 18.17 | 2.02 | 1.13 |
| Price / Net Operating Revenue (X) | 0.84 | 1.51 | 2.90 | 0.31 | 0.10 |
| EarningsYield | 0.03 | 0.03 | 0.01 | 0.12 | 0.31 |
After reviewing the key financial ratios for MK Proteins Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 0.30 (Mar 24) to 0.22, marking a decrease of 0.08.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.23. This value is below the healthy minimum of 3. It has decreased from 0.31 (Mar 24) to 0.23, marking a decrease of 0.08.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1.85. It has increased from 1.63 (Mar 24) to 1.85, marking an increase of 0.22.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 7.13. It has increased from 6.54 (Mar 24) to 7.13, marking an increase of 0.59.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.34, marking a decrease of 0.11.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.33. This value is within the healthy range. It has decreased from 0.44 (Mar 24) to 0.33, marking a decrease of 0.11.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.30. This value is within the healthy range. It has decreased from 0.41 (Mar 24) to 0.30, marking a decrease of 0.11.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 2. It has decreased from 0.29 (Mar 24) to 0.22, marking a decrease of 0.07.
- For PBDIT Margin (%), as of Mar 25, the value is 4.82. This value is below the healthy minimum of 10. It has decreased from 6.94 (Mar 24) to 4.82, marking a decrease of 2.12.
- For PBIT Margin (%), as of Mar 25, the value is 4.69. This value is below the healthy minimum of 10. It has decreased from 6.73 (Mar 24) to 4.69, marking a decrease of 2.04.
- For PBT Margin (%), as of Mar 25, the value is 4.27. This value is below the healthy minimum of 10. It has decreased from 6.29 (Mar 24) to 4.27, marking a decrease of 2.02.
- For Net Profit Margin (%), as of Mar 25, the value is 3.13. This value is below the healthy minimum of 5. It has decreased from 4.56 (Mar 24) to 3.13, marking a decrease of 1.43.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.08. This value is below the healthy minimum of 15. It has decreased from 18.35 (Mar 24) to 12.08, marking a decrease of 6.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 17.54. This value is within the healthy range. It has decreased from 26.54 (Mar 24) to 17.54, marking a decrease of 9.00.
- For Return On Assets (%), as of Mar 25, the value is 6.43. This value is within the healthy range. It has decreased from 11.64 (Mar 24) to 6.43, marking a decrease of 5.21.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has increased from 0.31 (Mar 24) to 0.54, marking an increase of 0.23.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.36. It has decreased from 2.44 (Mar 24) to 2.36, marking a decrease of 0.08.
- For Current Ratio (X), as of Mar 25, the value is 2.01. This value is within the healthy range. It has decreased from 2.53 (Mar 24) to 2.01, marking a decrease of 0.52.
- For Quick Ratio (X), as of Mar 25, the value is 0.12. This value is below the healthy minimum of 1. It has decreased from 0.19 (Mar 24) to 0.12, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.81. This value is below the healthy minimum of 4. It has increased from 2.73 (Mar 24) to 2.81, marking an increase of 0.08.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.68. This value is within the healthy range. It has decreased from 16.02 (Mar 24) to 11.68, marking a decrease of 4.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has decreased from 11.53 (Mar 24) to 8.60, marking a decrease of 2.93.
- For Enterprise Value (Cr.), as of Mar 25, the value is 264.44. It has decreased from 389.87 (Mar 24) to 264.44, marking a decrease of 125.43.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has decreased from 1.59 (Mar 24) to 0.98, marking a decrease of 0.61.
- For EV / EBITDA (X), as of Mar 25, the value is 20.49. This value exceeds the healthy maximum of 15. It has decreased from 22.85 (Mar 24) to 20.49, marking a decrease of 2.36.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For Price / BV (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has decreased from 6.07 (Mar 24) to 3.26, marking a decrease of 2.81.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.51 (Mar 24) to 0.84, marking a decrease of 0.67.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in MK Proteins Ltd:
- Net Profit Margin: 3.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.54% (Industry Average ROCE: 14.31%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.08% (Industry Average ROE: 12.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.12
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 26.5 (Industry average Stock P/E: 147.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Naraingarh Road, Village Garnala, Ambala District Haryana 134003 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Parvind Kumar | Chairman |
| Mr. Parmod Kumar | Managing Director |
| Mr. Vinod Kumar | Whole Time Director |
| Ms. Laxmi Mandal | Independent Director |
| Mr. Tej Mohan Singh | Independent Director |
| Mrs. Shipra Jain | Independent Director |
| Mr. Raj Kumar | Non Executive Director |
FAQ
What is the intrinsic value of MK Proteins Ltd?
MK Proteins Ltd's intrinsic value (as of 05 January 2026) is ₹5.26 which is 11.74% lower the current market price of ₹5.96, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹224 Cr. market cap, FY2025-2026 high/low of ₹9.78/5.37, reserves of ₹36 Cr, and liabilities of ₹80 Cr.
What is the Market Cap of MK Proteins Ltd?
The Market Cap of MK Proteins Ltd is 224 Cr..
What is the current Stock Price of MK Proteins Ltd as on 05 January 2026?
The current stock price of MK Proteins Ltd as on 05 January 2026 is ₹5.96.
What is the High / Low of MK Proteins Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of MK Proteins Ltd stocks is ₹9.78/5.37.
What is the Stock P/E of MK Proteins Ltd?
The Stock P/E of MK Proteins Ltd is 26.5.
What is the Book Value of MK Proteins Ltd?
The Book Value of MK Proteins Ltd is 1.96.
What is the Dividend Yield of MK Proteins Ltd?
The Dividend Yield of MK Proteins Ltd is 0.00 %.
What is the ROCE of MK Proteins Ltd?
The ROCE of MK Proteins Ltd is 12.9 %.
What is the ROE of MK Proteins Ltd?
The ROE of MK Proteins Ltd is 12.4 %.
What is the Face Value of MK Proteins Ltd?
The Face Value of MK Proteins Ltd is 1.00.